Phase
Condition
White Cell Disorders
Treatment
Albendazole
Ivermectin or albendazole
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants who come for check-ups at general practitioner, primary care unit, andSrivejchavat Premium Center have an absolute eosinophil count greater than 500cells/microliter with a white blood cell count less than 10,000 cells/microliter.
Age at least 18 years old
Consent to participate in research
Exclusion
Exclusion Criteria:
- Having any characteristics that need urgent care 1.1 Having history of unintendedsignificant weight loss is defined as the loss of body weight exceeding 10% within aspan of six months without deliberate attention.
1.2 Physical examination revealed a body temperature equal to or greater than 37.8 degrees Celsius, lymphadenopathy or hepatosplenomegaly.
1.3 CBC revealed blast cell
Receiving anthelminthic drug within 6 months
Underlying cancer (active stage), HIV, HBV, HCV, collagen vascular disease, activeTB
Allergy to albendazole, ivermectin, or metronidazole
Pregnancy or lactation
Serum transaminase higher than 2 times of upper normal limit
Taking medications that may induce eosinophilia within the past three months, suchas herbal supplements, NSAIDs, Salicylic acid, Carbamazepine, Colchicine,Nitrofurantoin, Dapsone, or Minocycline, was reported.
Study Design
Study Description
Connect with a study center
Prince of Songkla University - Hat Yai Campus: Prince of Songkla University
Hat Yai, Songkhla 90110
ThailandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.